Online Purchasing Account You are logged on as Guest. LoginRegister a New AccountShopping cart (Empty)
United States 

MEGACD40L® Protein (soluble) (human), (recombinant)

High activity, high purity CD40L protein for co-stimulatory activation of an immune response
ALX-522-110-C010 10 µg 670.00 USD
Do you need bulk/larger quantities?
  • Highly active MEGACD40L® oligomer mimics in vivo membrane-assisted CD40L aggregation and stimulation without the need for enhancers
  • High purity with low endotoxin levels
  • Experienced manufacturing results in consistent and dependable lot-to-lot performance
  • Optimized formulation for improved stability and enhanced activity
MEGACD40L® is a high activity protein in which two trimeric CD40 ligand molecules are artificially linked via the collagen domain of Adiponectin/ACRP30/AdipoQ. This protein very effectively simulates the natural membrane-assisted aggregation of CD40L in vivo.  It provides a simple and equally potent alternative to [CD40L+enhancer] combinations (Prod. No. ALX-850-064).

Product Details

Alternative Name:CD40L:ACRP30headless, CD154:ACRP30headless, TNFSF 5:ACRP30headless, gp39:ACRP30headless
Source:Produced in CHO cells. The extracellular domain of human CD40L (CD154) (aa 116-261) is fused at the N-terminus to mouse ACRP30headless (aa 18-111) and a FLAG®-tag.
UniProt ID:P29965 (human CD40L), Q60994 (mouse Adiponectin)
Concentration:0.1mg/ml after reconstitution.
Formulation:Lyophilized. Contains PBS.
Purity:≥90% (SDS-PAGE)
Purity Detail:Purified by multi-step chromatography.
Endotoxin Content:≤0.01EU/µg purified protein (LAL test; Cape Cod Associates).
Biological Activity:Binds to human CD40. Induces B cells activation (as demonstrated by dose-dependent upregulation of CD86).
Application Notes:Can be used to mediate immune and inflammatory responses, as a protein tool for pre-clinical studies in immunotherapy, to monitor patients undergoing chemotherapy and to mimic autoimmune phenotypes in vivo.
Reconstitution:Reconstitute with 100µl sterile water. Further dilutions should be made with medium containing 5% fetal calf serum.
Shipping:Blue Ice
Long Term Storage:-20°C
Use/Stability:Stable for at least 6 months after receipt when stored at -20°C.
Handling:Avoid freeze/thaw cycles. After reconstitution, prepare aliquots and store at -20°C.
Technical Info/Product Notes:FLAG is a registered trademark of Sigma-Aldrich Co.
Regulatory Status:RUO - Research Use Only
MEGACD40L® Protein (soluble) (human), (recombinant) Flow Cytometry
B cell lymphocyte activation by MEGACD40L® (Prod. No. ALX-522-110). Method: Peripheral Blood Mononuclear Cells (PBMCs) were incubated at 37°C, 5% CO2 for 48 hours in 48 well plates (1 x 106 cells/well). Each well contained 200µl serum free test media with serially diluted MEGACD40L®. After treatment, cells were washed and dual-stained with mouse anti-human CD19–PE and mouse anti-human CD86–APC and analyzed by flow cytometry. The data are presented as the percent of CD19 positive B cells that co-stain as CD86 positive, at each concentration of MEGACD40L®.
MEGACD40L® Protein (soluble) (human), (recombinant) Fig1
Graphical representation of MEGACD40L®, Soluble (human) (recombinant) (Prod. No. ALX-522-110).
MEGACD40L® Protein (soluble) (human), (recombinant) Flow Cytometry
PBMCs (peripheral blood mononuclear cells) were incubated at 37°C, 5% CO2 for 48 hours in 48 well plates (1 x 106 cells per well) containing 200µl serum free test media with serially diluted MEGACD40L® (Prod. No. ALX-522-110), CD40L (Prod. No. ALX-522-015), or CD40L + 2µg/ml Enhancer (Prod. No. ALX-804-034). After treatment the cells were washed 3X with PBS + 1% BSA. The cells were dual stained for 2 hours at 4°C with mouse anti-human CD19 (PE conjugate) and mouse anti-human CD86 (APC conjugate). The cells were washed 2X with PBS + 1% BSA, then re-suspended In PBS. Samples were analyzed on a BD Facs Calibur flow cytometer. The data is presented as the percent of CD86 positive cells per CD19 positive B cells at each concentration.
MEGACD40L® Protein (soluble) (human), (recombinant) Fig4
MEGACD40L® from 7 consecutive manufacturing lots was tested using a B-cell activation assay at 1000ng/mL.
MEGACD40L® Protein (soluble) (human), (recombinant) Fig5
MEGACD40L® was subjected to stability testing by storing the protein at the indicated temperature for 2 months. The protein was then tested for activity using a B cell activation assay. Results indicate MEGACD40L® retains activity under even harsh storage conditions.
Please mouse over
MEGACD40L® Protein (soluble) (human), (recombinant) Flow Cytometry MEGACD40L® Protein (soluble) (human), (recombinant) Fig1 MEGACD40L® Protein (soluble) (human), (recombinant) Flow Cytometry MEGACD40L® Protein (soluble) (human), (recombinant) Fig4 MEGACD40L® Protein (soluble) (human), (recombinant) Fig5

Product Literature References

Distinct stage-specific transcriptional states of B cells derived from human tonsillar tissue: D.A. Espinoza, et al.; JCI Insight 8, e155199 (2023), Abstract;
PD-1highCXCR5–CD4+ peripheral helper T cells promote CXCR3+ plasmablasts in human acute viral infection: H. Asashima, et al.; Cell Rep. 42, 111895 (2023), Abstract;
An optimized measles virus glycoprotein-pseudotyped lentiviral vector production system to promote efficient transduction of human primary B cells: E. Vamva, et al.; STAR Protoc. 3, 101228 (2022), Abstract;
In vitro 2D and 3D cancer models to evaluate compounds that modulate macrophage polarization: N.H. Madsen, et al.; Cell. Immunol. 378, 104574 (2022), Abstract;
Inverse Regulation of Confluence-Dependent ADAMTS13 and von Willebrand Factor Expression in Human Endothelial Cells: M. Popa, et al.; Thromb. Haemost. 122, 611 (2022), Abstract;
Role of CD40 ligand-mediated endothelial cell-monocyte interaction at atherosclerosis predilection sites: S. Lont, et al.; Biochem. Pharmacol. 206, 115298 (2022), Abstract;
Quantitative assessment of NFκB transcription factor activity: T.J. Hunter, et al.; J. Immunol. Methods 2021, 112954 (2021), Abstract;
T and B cell abnormalities, pneumocystis pneumonia, and chronic lymphocytic leukemia associated with an AIOLOS defect in patients: H.S. Kuehn, et al.; J. Exp. Med. 218, e20211118 (2021), Abstract;
Renal Fibrosis Is Significantly Attenuated Following Targeted Disruption of Cd40 in Experimental Renal Ischemia: S. Zhang, et al.; J. Am. Heart Assoc. 9, e014072 (2020), Abstract; Full Text
C1s Inhibition by BIVV009 (Sutimlimab) Prevents Complement-Enhanced Activation of Autoimmune Human B Cells In Vitro: P.A. Nikitin, et al.; J. Immunol. 202, 1200 (2019), Abstract; Full Text
CRISPR/Cas9 Screens Reveal Multiple Layers of B cell CD40 Regulation: C. Jiang, et al.; Cell Rep. 28, 1307 (2019), Abstract; Full Text
Epstein-Barr-Virus-Induced One-Carbon Metabolism Drives B Cell Transformation: L.W. Wang, et al.; Cell Metab. 30, 539 (2019), Abstract; Full Text
Type 1-programmed dendritic cells drive antigen-specific latency reversal and immune elimination of persistent HIV-1: J. Kristoff, et al.; EBioMedicine 43, 295 (2019), Abstract; Full Text
CD40L and TNF both activate the classical NF-κB pathway, which is not required for the CD40L induced alternative pathway in endothelial cells: J. Seigner, et al.; Biochem. Biophys. Res. Commun. 495, 1389 (2018), Abstract;
CD40L mediated alternative NFκB-signaling induces resistance to BCR-inhibitors in patients with mantle cell lymphoma: H. Rauert-Wunderlich, et al.; Cell Death Dis. 9, 86 (2018), Abstract; Full Text
Characterisation of anifrolumab, a fully human anti-interferon receptor antagonist antibody for the treatment of systemic lupus erythematosus: J.M. Riggs, et al.; Lupus Sci. Med. 5, e000261 (2018), Abstract; Full Text
Engineering protein-secreting plasma cells by homology-directed repair in primary human B cells: K.L. Hung, et al.; Mol. Ther. 26, 456 (2018), Abstract;
High PD-L1/CD86 MFI ratio and IL-10 secretion characterize human regulatory dendritic cells generated for clinical testing in organ transplantation: A.F. Zahorchak, et al.; Cell. Immunol. 323, 9 (2018), Abstract;
In vitro antineoplastic effects of auranofin in canine lymphoma cells: H. Zhang, et al.; BMC Cancer 18, 522 (2018), Abstract; Full Text
Arginine methylation catalyzed by PRMT1 is required for B cell activation and differentiation: S. Infantino, et al.; Nat. Commun. 8, 891 (2017), Application(s): B-cell activation, Abstract; Full Text
B-cell activation with CD40L or CpG measures the function of B-cell subsets and identifies specific defects in immunodeficient patients: E. Marasco, et al.; Eur. J. Immunol. 47, 131 (2017), Application(s): Human PBMC culture, Abstract; Full Text
CD40 signaling in Graves disease is mediated through canonical and noncanonical thyroidal nuclear factor κB activation: H.J. Lee, et al.; Endocrinology 158, 410 (2017), Abstract; Full Text
Cutting Edge: Active TGF-β1 Released from GARP/TGF-β1 Complexes on the Surface of Stimulated Human B Lymphocytes Increases Class-Switch Recombination and Production of IgA: O. Dedobbeleer, et al.; J. Immunol. 199, 391 (2017), Abstract; Full Text
Down‐regulation of CD73 on B cells of patients with viremic HIV correlates with B cell activation and disease progression: E.S. Kim, et al.; J. Leukoc. Biol. 101, 1263 (2017), Abstract;
Human secretory IgM emerges from plasma cells clonally related to gut memory B cells and targets highly diverse commensals: G. Magri, et al.; Immunity 47, 118 (2017), Abstract; Full Text
Regulation of cell surface CB2 receptor during Human B cell activation and differentiation: J.T. Castaneda, et al.; J. Neuroimmune Pharmacol. 12, 544 (2017), Abstract; Full Text
CD40 expression in fibrocytes Is induced by TSH: potential synergistic immune activation: T. Mester, et al.; PLoS One 11, e0162994 (2016), Abstract; Full Text
Distinct TLR-mediated cytokine production and immunoglobulin secretion in human newborn naïve B cells: M.A. Pettengill, et al.; Innate Immun. 22, 433 (2016), Abstract; Full Text
Expression of HIV-1 matrix protein p17 and association with B-cell lymphoma in HIV-1 transgenic mice: V.A. Carroll, et al.; PNAS 113, 13168 (2016), Application(s): Human B cells culture, Abstract; Full Text
T-helper signals restore B-cell receptor signaling in autoreactive anergic B cells by upregulating CD45 phosphatase activity: P. Szodoray, et al.; J. Allergy Clin. Immunol. 138, 839 (2016), Application(s): Cell culture, Abstract;
A human monoclonal antibody targeting the conserved staphylococcal antigen IsaA protects mice against Staphylococcus aureus bacteremia: S. van den Berg, et al.; Int. J. Med. Microbiol. 305, 55 (2015), Application(s): ELISA, PCR of human blood samples, Abstract;
CD40L Induces Functional Tunneling Nanotube Networks Exclusively in Dendritic Cells Programmed by Mediators of Type 1 Immunity: C. Zaccard, et al.; J. Immunol. 194, 1047 (2015), Application(s): Activation of mature human dendritic cells, Abstract;
Detection of IκB degradation dynamics and IκB-α ubiquitination: P. Starokadomskyy, et al.; Methods Mol. Biol. 1280, 15 (2015), Abstract;
Establishing the pig as a large animal model for vaccine development against human cancer: N.H. Overgaard, et al.; Front. Genet. 6, 286 (2015), Abstract; Full Text
Haploinsufficiency of the NF-κB1 subunit p50 in common variable immunodeficiency: M. Fliegauf, et al.; Am. J. Hum. Genet. 97, 389 (2015), Abstract; Full Text
Mechanism and functional impact of CD40 ligand-induced von Willebrand factor release from endothelial cells: K. Möller, et al.; Thromb. Haemost. 113, 1095 (2015), Abstract;
NF-κB, p38 MAPK, ERK1/2, mTOR, STAT3 and increased glycolysis regulate stability of paricalcitol/dexamethasone-generated tolerogenic dendritic cells in the inflammatory environment: K. Danova, et al.; Oncotarget 6, 14123 (2015), Abstract; Full Text
Phenotypic Approaches to Identify Inhibitors of B Cell Activation: E. B. Rex, et al.; J. Biomol. Screen. 20, 876 (2015), Application(s): Assay, Abstract; Full Text
Systemic agonistic anti-CD40 treatment of tumor-bearing mice modulates hepatic myeloid-suppressive cells and causes immune-mediated liver damage: J. Medina-Echeverz, et al.; Cancer Immunol. Res. 3, 557 (2015), Abstract; Full Text
A GPBAR1 (TGR5) small molecule agonist shows specific inhibitory effects on myeloid cell activation in vitro and reduces experimental autoimmune encephalitis (EAE) in vivo: N. Lewis, et al.; PLoS One 9, e100883 (2014), Application(s): Assay of human PBMC, Abstract; Full Text
Development of a novel anti-canine CD20 monoclonal antibody with diagnostic and therapeutic potential: D. Ito, et al.; Leuk. Lymphoma 56, 219 (2014), Application(s): Analysis of canine B-cell lymphoma cells, Abstract;
Exosomes Derived from Burkitt’s Lymphoma Cell Lines Induce Proliferation, Differentiation, and Class-Switch Recombination in B Cells: C. Gutzeit, et al.; J. Immunol. 192, 5852 (2014), Application(s): PCR, Assay of human B cells, Abstract; Full Text
Preclinical evaluation of the novel, orally bioavailable Selective Inhibitor of Nuclear Export (SINE) KPT-335 in spontaneous canine cancer: results of a phase I study: C. London, et al.; PLoS One 9, e87585 (2014), Application(s): Analysis of canine tumor cells by WB, FLOW, Abstract; Full Text
Thyrotropin receptor and CD40 mediate interleukin-8 expression in fibrocytes: implications for thyroid-associated ophthalmopathy (an American Ophthalmological Society thesis).: R. Douglas, et al.; Trans. Am. Ophthalmol. Soc. 12, 26 (2014), Application(s): In vitro analysis of human fibrocytes, Abstract; Full Text
AMPKα1 deficiency amplifies proinflammatory myeloid APC activity and CD40 signaling: K.C. Carroll, et al.; J. Leukoc. Biol. 94, 1113 (2013), Abstract;
Blood CD4+CD45RO+CXCR5+ T cells are decreased but partially functional in signal transducer and activator of transcription 3 deficiency: F. Mazerolles, et al.; J. Allergy Clin. Immunol. 131, 1146 (2013), Application(s): Assay of blood cells, Abstract;
CD40 ligand is necessary and suffi cient to support primary diff use large B-cell lymphoma cells in culture: a tool for in vitro preclinical studies with primary B-cell malignancies: D. Ito, et al.; Leuk. Lymphoma 53, 1390 (2012), Application(s): Flow cytometry of human B cells, Abstract; Full Text
HIV-1 gp120 impairs the induction of B cell responses by TLR9-activated plasmacytoid dendritic cells: N.P. Chung, et al.; J. Immunol. 189, 5257 (2012), Application(s): Activation of dendritic cells, Abstract; Full Text
Immunodeficiency, autoinflammation and amylopectinosis in humans with inherited HOIL-1 and LUBAC deficiency: B. Boisson, et al.; Nat. Immunol. 13, 1178 (2012), Application(s): ELISA of human blood cells, Abstract; Full Text
Interleukin-6 Production in CD40-Engaged Fibrocytes in Thyroid-Associated Ophthalmopathy: Involvement of Akt and NF-κB: E.F. Gillespie, et al.; Invest. Ophthalmol. Vis. Sci. 53, 7746 (2012), Application(s): CD40 ligation, induction and signaling in Graves' orbital fibroblasts (GOFB) and fibrocytes, Abstract; Full Text
Siglec-7 tetramers characterize B-cell subpopulations and leukemic blasts: F. Gieseke, et al.; Eur. J. Immunol. 42, 2176 (2012), Application(s): ELISA of human B cells , Abstract; Full Text
Stromal endothelial cells establish a bidirectional crosstalk with chronic lymphocytic leukemia cells through the TNF-related factors BAFF, APRIL and CD40L: M. Cols, et al.; J. Immunol. 188, 6071 (2012), Application(s): UVEC & MVEC entothelial cell culture, Abstract; Full Text
New mechanism of X-linked anhidrotic ectodermal dysplasia with immunodeficiency: impairment of ubiquitin binding despite normal folding of NEMO protein: M. Hubeau, et al.; Blood 118, 926 (2011), Abstract;
Reconstitution of huPBL-NSG mice with donor-matched dendritic cells enables antigen-specific T-cell activation: A. Harui, et al.; J. Neuroimmune Pharmacol. 6, 148 (2011), Application(s): Activation of dendritic cells, Abstract; Full Text
Study of patients with Hyper-IgM type IV phenotype who recovered spontaneously during late childhood and review of the literature: N. Karaca, et al.; Eur. J. Pediatr. 170, 1039 (2011), Application(s): Determining human B-cell function in Hyper-IgM blood samples, Abstract;
Human TRAF3 adaptor molecule deficiency leads to impaired Toll-like Receptor 3 response and susceptibility to Herpes Simplex Encephalitis: R. Perez de Diego, et al.; Immunity 33, 400 (2010), Abstract;
Multimeric soluble CD40 ligand (sCD40L) efficiently enhances HIV specific cellular immune responses during DNA prime and boost with attenuated poxvirus ventors MVA and NYVAC expressing HIV antigens : C.E. Gomez, et al.; Vaccine 27, 3165 (2009), Abstract;
Impaired CD40L signaling is a cause of defective IL-12 and TNF-alpha production in Sezary syndrome: circumvention by hexameric soluble CD40L: L.E. French, et al.; Blood 105, 219 (2005), Abstract; Full Text
Two adjacent trimeric Fas ligands are required for Fas signaling and formation of a death-inducing signaling complex: N. Holler, et al.; Mol. Cell. Biol. 23, 1428 (2003), Abstract; Full Text

Related Products

MEGACD40L® Protein (soluble) (mouse), (recombinant) 

High activity, high purity CD40L protein for co-stimulatory activation of an immune response
Produced in CHO cells. The extracellular domain of mouse CD40L (CD154) (aa 115-260) is fused at the N-terminus to mouse ACRP30headless (aa 18-111) and a FLAG®-tag., ≥95% (SDS-PAGE) | Print as PDF
ALX-522-120-C010 10 µg 716.00 USD
Do you need bulk/larger quantities?

CD40L, soluble (human) (recombinant) set 

Ligand plus enhancer for improved stability and enhanced immune activation.
Produced in E. coli. The extracellular domain of human CD40L (CD154) (aa 116-261) is fused at the N-terminus to a linker peptide (6 aa) and a FLAG®-tag., ≥95% (SDS-PAGE)., FUNC | Print as PDF
ALX-850-064-KI01 1 Set 664.00 USD
Do you need bulk/larger quantities?

CD40L (human) monoclonal antibody (blocking) (MK13A4) 

Flow Cytometry, FUNC | Print as PDF
ALX-805-037-C100 100 µg Purified 386.00 USD
Do you need bulk/larger quantities?

CD40L (soluble) (human), (recombinant) 

Increases the stimulation of B cells
Produced in E. coli. The extracellular domain of human CD40L (CD154) (aa 116-261) is fused at the N-terminus to a linker peptide (6 aa) and a FLAG®-tag., ≥95% (SDS-PAGE), ELISA | Print as PDF
ALX-522-015-C010 10 µg 214.00 USD
ALX-522-015-2010 2x10 µg 299.00 USD
ALX-522-015-6010 6x10 µg SuperPack 717.00 USD
Do you need bulk/larger quantities?

Fc (human):CD40L (soluble) (human), (recombinant) 

Produced in HEK 293 cells. The extracellular domain of human CD40L (CD154) (aa 116-261) is fused at the N-terminus to the Fc portion of human IgG1 and a linker peptide (20 aa)., ≥90% (SDS-PAGE), ELISA, FUNC | Print as PDF
ALX-522-076-C010 10 µg 561.00 USD
Do you need bulk/larger quantities?

CD40 polyclonal antibody 

Purified from rabbit serum., WB | Print as PDF
ADI-CSS-180-D 50 µg 213.00 USD
ADI-CSS-180-F 200 µg 512.00 USD
Do you need bulk/larger quantities?

CD40 (human):Fc (human), (recombinant) 

Produced in HEK 293 cells. The cysteine-rich region (aa 21-193) of human CD40 is fused to the Fc portion of human IgG1., ≥95% (SDS-PAGE), ELISA | Print as PDF
ALX-522-016-C050 50 µg 486.00 USD
Do you need bulk/larger quantities?

CD40L, soluble (human) ELISA kit (high sensitivity) 

ELISA | Print as PDF
ALX-850-311-KI01 96 wells 924.00 USD
Do you need bulk/larger quantities?

Product Toolbox


Certificate of Analysis


By target:
By biological activity:
CD40L Recombinant protein
By catalog section:


Technical Service
Customer Service

Related Literature

Immunology - Innovative Products to Study the Immune Response
 	 Immunology - Innovative Products to Study the Immune Response
Download as PDF

Product Flyers
MEGACD40L® - Cited Samples
MEGACD40L® - Cited Samples
Download as PDF

Product Flyers
True Immune Activation. Highest-Purity MEGACD40L®
True Immune Activation. Highest-Purity MEGACD40L®
Download as PDF

All new literature pieces